Hassab A H, Elbordiny M M, Elghandour A H, Sorour A F, Swelem R S
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Egypt.
Egypt J Immunol. 2011;18(2):77-93.
Chronic lymphocytic leukemia (CLL) follows an extremely variable clinical course with overall survival times ranging from months to decades. The clinical staging systems do not allow one to predict if and at what rate there will be disease progression in an individual patient diagnosed with early stage disease. There has been intensive work on clinical and biological factors of potential prognostic relevance that may add to the classic assessment provided by the staging systems. Among these are: Laboratory parameters reflecting the tumor burden or disease activity such as lymphocyte count, lactate dehydrogenase (LDH) elevation, bone marrow infiltration pattern or lymphocyte doubling time (LDT), serum markers such as soluble CD23, beta2-microglobulin (beta2-MG) or thymidine kinase (TK), and genetic markers of tumor cells such as genomic aberrations, the mutation status of the variable segments of immunoglobulin heavy chain genes (VH), or surrogate markers for these factors (CD38, ZAP-70, LPL). Thirty patients were included in our study, the investigation included CD38 expression, ZAP-70 expression, and interphase Fluorescence In Situ Hybridization (FISH) for the detection of trisomy 12, del 13q14.3, del 17p13, and del 11q22.3. Our results showed positive statistical significant correlation between ZAP-70 expression and CD38 expression with some of the chromosomal aberrations encompassing bad prognosis as ATM and p53. Also CD38 expression was positively correlated with trisomy 12 and p53 deletions. Chromosomal aberrations were found to be present in 76.6% of our patients with 13q deletion as the most frequent abnormality in our patients (46.7%), followed by trisomy 12 (36.7%), then ATM and p53 deletion (26.7%) each. Another interesting finding in our study is the fact that 100% of the ZAP-70 positive patients were of bad prognosis, 58.3% of the CD38 positive cases, 81.8% of the positive trisomy 12 cases, 100% of the ATM deletion, 62.5% of the p53 deletion, and 64.3% of the 13q- cases were also of bad prognosis, which indicates that ZAP-70, trisomy 12, and ATM deletion are powerful indicators of prognosis. We conclude that FISH for the detection of the most important chromosomal aberrations in CLL is an important laboratory parameter that is recommended for assessment and correlation with simultaneous evaluation of ZAP-70 and CD38 expression which could help in the prediction of outcome of CLL patients.
慢性淋巴细胞白血病(CLL)的临床病程极具变异性,总生存时间从数月到数十年不等。临床分期系统无法让人们预测个别诊断为早期疾病的患者是否会出现疾病进展以及进展速度如何。针对可能具有预后相关性的临床和生物学因素已开展了大量研究工作,这些因素可能会补充分期系统所提供的经典评估。其中包括:反映肿瘤负荷或疾病活动的实验室参数,如淋巴细胞计数、乳酸脱氢酶(LDH)升高、骨髓浸润模式或淋巴细胞倍增时间(LDT);血清标志物,如可溶性CD23、β2-微球蛋白(β2-MG)或胸苷激酶(TK);以及肿瘤细胞的遗传标志物,如基因组畸变、免疫球蛋白重链基因可变区(VH)的突变状态,或这些因素的替代标志物(CD38、ZAP-70、LPL)。我们的研究纳入了30例患者,调查包括CD38表达、ZAP-70表达,以及用于检测12号染色体三体、13q14.3缺失、17p13缺失和11q22.3缺失的间期荧光原位杂交(FISH)。我们的结果显示,ZAP-70表达与CD38表达之间存在统计学显著正相关,且一些染色体畸变与不良预后相关,如ATM和p53。此外,CD38表达与12号染色体三体和p53缺失呈正相关。在我们的患者中,76.6%存在染色体畸变,其中13q缺失是最常见的异常(46.7%),其次是12号染色体三体(36.7%),然后是ATM和p53缺失(各26.7%)。我们研究中的另一个有趣发现是,100%的ZAP-70阳性患者预后不良,58.3%的CD38阳性病例、81.8%的12号染色体三体阳性病例、100%的ATM缺失病例、62.5%的p53缺失病例以及64.3%的13q-病例预后也不良,这表明ZAP-70、12号染色体三体和ATM缺失是强大的预后指标。我们得出结论,用于检测CLL中最重要染色体畸变的FISH是一项重要的实验室参数,建议将其与ZAP-70和CD38表达的同步评估相结合进行评估和关联,这有助于预测CLL患者的预后。